Overview

Rezafungin Prophylaxis in Liver Transplant

Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is an interventional study to evaluate the efficacy of rezafungin, a new echinocandin, for the prevention of invasive fungal infections (IFIs) after liver transplantation. Patients who receive rezafungin will be compared to a similar group of patients who underwent liver transplantation in the preceding two years for the incidence of IFIs.
Phase:
PHASE3
Details
Lead Sponsor:
Fernanda P Silveira, MD, MS
Collaborator:
Melinta Therapeutics
Treatments:
Fluconazole
Rezafungin
Voriconazole